ACCESSWIRE
17 Mar 2023, 16:31 GMT+10
GOTHENBURG, SWEDEN / ACCESSWIRE / March 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson's disease, today announced that it will present new data in an oral presentation and hold three poster presentations at the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD ™ 2023, held on March 28- April 1, 2023, in Gothenburg, Sweden.
One abstract has been selected to be presented as an oral presentation during the session Symposium: Exploring new targets in AD, PD and LBD:
Three abstracts have been accepted as poster presentations and will be available to view online and onsite during the full length of the congress:
The presentations will also be available on IRLAB's website following the presentations.
For more details about the AD/PD™ 2023 congress, please visit: https://adpd.kenes.com/
About IRLAB
IRLAB discovers and develops novel treatments of Parkinson's disease and other CNS disorders. The company's most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in Phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson's. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to the development and commercialization of mesdopetam.
IRLAB has discovered and generated all its drug candidates and continues to discover innovative drug candidates for the treatment of CNS disorders through its proprietary systems biology-based Integrative Screening Process (ISP) research platform. In addition to IRLAB's strong clinical pipeline, the company is also progressing three preclinical programs, IRL942, IRL757, and IRL1117, towards Phase I studies. IRLAB is listed on Nasdaq Stockholm. More information on www.irlab.se.
For more information
Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se
Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se
Attachments
IRLAB to hold four presentations at scientific congress AD/PD™ 2023
SOURCE: IRLAB Therapeutics
Get a daily dose of Albuquerque Express news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Albuquerque Express.
More InformationNASSAU, The Bahamas: The Bahamas police says a woman from the U.S. died after she was attacked by a shark ...
BEIJING, China: President Xi Jinping is set to visit Vietnam on December 12 and 13, where he will engage with ...
WASHINGTON, DC - Within hours of blocking a UN Security Council resolution from demanding a ceasefire in the current Mideast ...
WASHINGTON D.C.: In a sign of the challenges ahead for his 2024 re-election bid, a new Reuters/Ipsos poll showed that ...
Israel has acknowledged and thanked the United States and President Joe Biden for standing firmly by Israel's side at the ...
NEW YORK: This week, New York City officials said that one person was killed and six others were injured when ...
ARLINGTON, Virginia: After pulling ahead of Airbus in closely monitored fleet renewal discussions, Boeing is nearing a deal to sell ...
TOKYO, Japan: Japan, Britain, and Italy are set to establish a new collaborative organization and industry group dedicated to developing ...
LOS ANGELES, California: This week, members of the SAG-AFTRA actors union approved a three-year contract with major studios, formally ending ...
LAS VEGAS, Nevada: The U.S. Transportation Department has allocated US$3 billion for a $12 billion Las Vegas to Southern California ...
WASHINGTON D.C.: U.S. gasoline prices could fall below US$3 a gallon for the first time since 2021 and are currently ...
WASHINGTON D.C.: To fix issues that could lead to further bank failures in the U.S., such as the collapse of ...